Tolvaptan Oral Tablet
( DrugBank: Tolvaptan / KEGG DRUG: Tolvaptan )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 72 | 下垂体性ADH分泌異常症 | 8 |
72. 下垂体性ADH分泌異常症
臨床試験数 : 41 / 薬物数 : 27 - (DrugBank : 8) / 標的遺伝子数 : 7 - 標的パスウェイ数 : 10
Showing 1 to 8 of 8 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-173512 | 02/3/201720170302 | 08/02/201720170208 | Tolvaptan SIADH Study | A Multicenter, Uncontrolled, Open-label, Dose-titration Trial to Investigate theEfficacy and Safety of Tolvaptan Tablets in Patients With Hyponatremia inSyndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) A Multicenter, Uncontrolled, Open-label, Dose-titration Trial to Investigate theEfficacy and Safety ... | Syndrome of inappropriate secretion of antidiuretic hormones (SIADH) | Intervention name : Tolvaptan INN of the intervention : - Dosage And administration of the intervention : Tolvaptan tablets at 7.5, 15, 30 (one tablet each), or 60 mg (two 30 mg tablets) will be orally administered once daily after breakfast for up to 30 days. Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - Intervention name : Tolvaptan INN of the intervention : - Dosage And administration of the interventio ... | Otsuka Pharmaceutical Co., LTD. | NULL | complete | 20 | 85 | BOTH | 16 | Phase 3 | Japan |
| 2 | NCT03048747 (ClinicalTrials.gov) | March 2, 201720170302 | 7/2/201720170207 | A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptanin Patients With Hyponatremia ... | A Multicenter, Uncontrolled, Open-label, Dose-titration Trial to Investigate the Efficacy and Safety of Tolvaptan Tablets in Patients With Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) A Multicenter, Uncontrolled, Open-label, Dose-titration Trial to Investigate the Efficacy and Safety ... | Syndrome of Inappropriate Antidiuretic Hormone Secretion | Drug: Tolvaptan Oral Tablet | Otsuka Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | 85 Years | All | 16 | Phase 3 | Japan |
| 3 | EUCTR2014-001973-15-DK (EUCTR) | 18/11/201420141118 | 27/06/201420140627 | The effcts of tolvaptan on renal handling of water and salt, hormones in the blood at the circulation, during blocking of the nitric oxide (NO) system in patients with autosomal dominant polycystic kidney disease The effcts of tolvaptanon renal handling of water and salt, hormones in the blood at the circulation ... | Renal Handling of Water and Sodium in Autosomal Dominant Polycystic Kidney Disease.The effects of tolvaptan on renal handling of water and sodium , vasoactive hormones and central hemodynamics during baseline conditions and after inhibition of the nitric oxide system in patients with autosomal dominant polycystic kidney disease - TOPO Renal Handling of Water and Sodium in Autosomal Dominant Polycystic Kidney Disease.The effects of to ... | HyponatreamiaSIADH ( Syndrome of Inappropriate Antidiuretic Hormone Secretion) OverhydrationAutosomal dominant polycystic kidney disease MedDRA version: 17.0;Level: LLT;Classification code 10021038;Term: Hyponatremia;System Organ Class: 100000004861 MedDRA version: 17.0;Classification code 10040626;Term: SIADH;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Physiological processes [G07] HyponatreamiaSIADH ( Syndrome of Inappropriate Antidiuretic Hormone Secretion) OverhydrationAutosoma ... | Trade Name: Samsca Product Name: Tolvaptan Product Code: C03XA01 INN or Proposed INN: Tolvaptan Other descriptive name: TOLVAPTAN Trade Name: Samsca Product Name: Tolvaptan Product Code: C03XA01 INN or Proposed INN: Tolvaptan Other de ... | University Clinic in Nephrology and Hypertension, Department of Medical Research | NULL | Not Recruiting | Female: yes Male: yes | Denmark | ||||
| 4 | EUCTR2013-003800-38-DK (EUCTR) | 24/02/201420140224 | 09/12/201320131209 | The effects of tolvaptan on renal handeling of water and salt, hormones in the blood and the circulation, during blocking of the nitric oxide (NO) system in healthy subjects. A dose-response study. The effects of tolvaptanon renal handeling of water and salt, hormones in the blood and the circulat ... | The effects of tolvaptan on renal handling of water and sodium, vasoactive hormones and circulatory system, during basal conditions and during inhibition of the nitric oxide system in healthy subjects. A dose-response study. - DOVA The effects of tolvaptanon renal handling of water and sodium, vasoactive hormones and circulatory s ... | HyponatremiaSIADH (Syndrome of Inappropriate Antidiuretic Hormone secretion) MedDRA version: 14.1;Level: LLT;Classification code 10021038;Term: Hyponatremia;System Organ Class: 100000004861 MedDRA version: 14.1;Classification code 10040626;Term: SIADH;System Organ Class: 100000004860;Therapeutic area: Body processes [G] - Physiological processes [G07] HyponatremiaSIADH (Syndrome of Inappropriate Antidiuretic Hormone secretion) MedDRA version: 14.1;Le ... | Trade Name: Samsca Product Name: Tolvaptan Product Code: C03XA01 INN or Proposed INN: Tolvaptan Other descriptive name: TOLVAPTAN Trade Name: Samsca Product Name: Tolvaptan Product Code: C03XA01 INN or Proposed INN: Tolvaptan Other de ... | Department of Medical Research | NULL | Not Recruiting | Female: yes Male: yes | 22 | Phase 2 | Denmark | ||
| 5 | NCT02009878 (ClinicalTrials.gov) | November 201320131100 | 9/12/201320131209 | A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) A PK Study of 3 Dosages of Tolvaptanin Patients With Syndrome of Inappropriate Antidiuretic Hormone ... | A Phase 1b, Multicenter, Pilot, Randomized, Double-blind Trial to Determine the Pharmacokinetics and Pharmacodynamics of Orally Administered Tolvaptan 3.75, 7.5, and 15 mg Tablets in Subjects With Syndrome of Inappropriate Antidiuretic Hormone Secretion A Phase 1b, Multicenter, Pilot, Randomized, Double-blind Trial to Determine the Pharmacokinetics and ... | Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) | Drug: tolvaptan | Otsuka Pharmaceutical Development & Commercialization, Inc. | NULL | Completed | 18 Years | N/A | All | 30 | Phase 1/Phase 2 | Czech Republic;Denmark;Germany;Hungary;Spain;Sweden;United Kingdom |
| 6 | EUCTR2012-001169-33-DK (EUCTR) | 02/07/201220120702 | 14/06/201220120614 | Effects of the diuretic tolvaptan on nitric oxide system | Effects of tolvaptan on renal sodium and water handling and circulation during inhibition of the nitric oxide system in healthy subjects - SAFA Effects of tolvaptanon renal sodium and water handling and circulation during inhibition of the nitr ... | SIADH (Syndrome of inappropriate ADH production)OverhydrationHyponatrimia MedDRA version: 14.1;Level: LLT;Classification code 10021038;Term: Hyponatremia;System Organ Class: 10027433 - Metabolism and nutrition disorders MedDRA version: 14.1;Classification code 10040626;Term: SIADH;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Body processes [G] - Physiological processes [G07] SIADH (Syndrome of inappropriate ADH production)OverhydrationHyponatrimia MedDRA version: 14.1;Level ... | Trade Name: Samsca Product Name: Tolvaptan INN or Proposed INN: Tolvaptan Other descriptive name: TOLVAPTAN Trade Name: Samsca Product Name: Tolvaptan INN or Proposed INN: Tolvaptan Other descriptive name: TOLVA ... | Department of Medical Research | NULL | Not Recruiting | Female: yes Male: yes | 20 | Phase 2 | Denmark | ||
| 7 | NCT00201994 (ClinicalTrials.gov) | November 200320031100 | 13/9/200520050913 | SALT-2 Trial Study of Ascending Levels of Tolvaptan in Hyponatremia | Multicenter, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of the Effects of Titrated Oral Tolvaptan Tablets in Patients With Hyponatremia, Study 2 Multicenter, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of the Effects ... | Hyponatremia;Water Intoxication;Inappropriate ADH Syndrome;Water-electrolyte Imbalance | Drug: Tolvaptan | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Pharmaceutical Co., Ltd. | Completed | 18 Years | N/A | Both | 243 | Phase 3 | Germany |
| 8 | NCT00072683 (ClinicalTrials.gov) | April 200320030400 | 7/11/200320031107 | SALT Trial” Study of Ascending Levels of Tolvaptan in Hyponatremia | Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of the Effects of Titrated Oral Tolvaptan Tablets in Patients With Hyponatremia Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of the Effects ... | Hyponatremias;Water Intoxication;Inappropriate ADH Syndrome;Water-Electrolyte Imbalances | Drug: tolvaptan | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Pharmaceutical Co., Ltd. | Completed | 18 Years | N/A | Both | 240 | Phase 3 | United States |